Funder
National Institutes of Health
Merck & Co Inc
Canadian Foundation for AIDS Research
Canadian Institutes of Health Research
The Philadelphia Foundation
Canada Excellence Research Chairs
Michael Smith Foundation for Health Research
Subject
Pharmacology,Biochemistry
Reference59 articles.
1. A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population;Chawla;Infect. Dis. Ther.,2018
2. Zicari, S., Sessa, L., Cotugno, N., Ruggiero, A., Morrocchi, E., Concato, C., Rocca, S., Zangari, P., Manno, E.C., and Palma, P. (2019) Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Viruses. 11, 200.
3. Besnard, E., Hakre, S., Kampmann, M., Lim, H.W., Hosmane, N.N., Martin, A., Bassik, M.C., Verschueren, E., Battivelli, E., Chan, J., Svensson, J.P., Gramatica, A., Conrad, R.J., Ott, M., Greene, W.C., Krogan, N.J., Siliciano, R.F., Weissman, J.S., and Verdin, E. (2016) The mTOR complex controls HIV latency. Cell Host Microbe. 14, 785-797.
4. Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription;Hayashi;Antiviral Res.,2017
5. Inhibitors of signaling pathways that block reversal of HIV-1 latency;Vargas;Antimicrob. Agents Chemother.,2019
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献